NCT06385925View on ClinicalTrials.gov

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

April 29, 2024

Primary Completion Date

October 30, 2026

Study Completion Date

April 30, 2027

Conditions
Malignant Neoplasm
Interventions
DRUG

TSN1611

TSN1611 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.

Trial Locations (6)

22031

RECRUITING

NEXT Virginia, Fairfax

77030

RECRUITING

MD Anderson Cancer Center, Houston

78229

RECRUITING

NEXT Oncology, San Antonio

100142

RECRUITING

Beijing Cancer Hospital, Beijing, China, Beijing

200030

RECRUITING

Shanghai Chest Hospital, Shanghai, China, Shanghai

200032

RECRUITING

Shanghai Zhongshan Hospital, Shanghai, China, Shanghai

All Listed Sponsors
lead

Tyligand Pharmaceuticals (Suzhou) Limited

INDUSTRY